Literature DB >> 15898987

Common and distinct signalling cascades in the production of tumour necrosis factor-alpha and interleukin-13 induced by lipopolysaccharide in RBL-2H3 cells.

Y Gon1, S Nunomura, C Ra.   

Abstract

BACKGROUND: Activation of mast cells by lipopolysaccharide (LPS) results in the production of TNF-alpha and IL-13. TNF-alpha and IL-13 are key mediators in the development of neutrophilic and allergic inflammation, respectively. LPS-induced TNF-alpha and IL-13 production in mast cells has been reported to be mediated by Toll-like receptor 4 (TLR4) signalling, but differences in signal transduction mechanisms leading to the production of these cytokines are not clearly defined.
OBJECTIVE: We investigated the molecular mechanisms responsible for LPS-induced TNF-alpha and IL-13 production in mast cells.
METHODS: TNF-alpha and IL-13 production by LPS was assessed by transfecting RBL-2H3 cells with dominant-negative (DN) expression vectors.
RESULTS: Transfection of RBL-2H3 cells with plasmids encoding DN mutants of myeloid differentiation protein (MyD88) and TNFR-associated factor (TRAF6) inhibited both LPS-induced TNF-alpha and IL-13 production. IkappaBalpha-DN inhibited LPS-induced production of TNF-alpha, but not IL-13. We also found that inhibition of p38 kinase suppressed both TNF-alpha and IL-13 induction by LPS, and inhibition of JNK reduced IL-13 production, but not TNF-alpha. Furthermore, we found that protein kinase R (PKR) was activated by LPS in these cells. Treatment with 2-aminopurine, a PKR inhibitor, attenuated LPS-induced nuclear factor-kappaB activation and TNF-alpha production, whereas inhibition of PKR had little effect on IL-13 production.
CONCLUSION: These findings indicate that the production of TNF-alpha and IL-13 by LPS required TLR4/MyD88/TRAF6 signalling as a common pathway of mast cell-mediated inflammation. We furthermore found that TNF-alpha and IL-13 production were differentially regulated by signalling cascades through PKR and mitogen-activated protein kinases downstream of TRAF6 in mast cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15898987     DOI: 10.1111/j.1365-2222.2005.02223.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  7 in total

1.  RBL-2H3 cells are an imprecise model for mast cell mediator release.

Authors:  Egle Passante; Carsten Ehrhardt; Helen Sheridan; Neil Frankish
Journal:  Inflamm Res       Date:  2009-03-20       Impact factor: 4.575

2.  Deficiencies in elements involved in TLR4-receptor signalling in RBL-2H3 cells.

Authors:  E Passante; N Frankish
Journal:  Inflamm Res       Date:  2010-03       Impact factor: 4.575

Review 3.  The RBL-2H3 cell line: its provenance and suitability as a model for the mast cell.

Authors:  Egle Passante; Neil Frankish
Journal:  Inflamm Res       Date:  2009-08-09       Impact factor: 4.575

4.  Mast cell TLR2 signaling is crucial for effective killing of Francisella tularensis.

Authors:  Annette R Rodriguez; Jieh-Juen Yu; M Neal Guentzel; Christopher S Navara; Karl E Klose; Thomas G Forsthuber; James P Chambers; Michael T Berton; Bernard P Arulanandam
Journal:  J Immunol       Date:  2012-04-23       Impact factor: 5.422

5.  Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin.

Authors:  Rabab El Mezayen; Mohamed El Gazzar; Michael C Seeds; Charles E McCall; Stephen C Dreskin; Mark R Nicolls
Journal:  Immunol Lett       Date:  2007-05-25       Impact factor: 3.685

Review 6.  Role of Leukotriene B4 Receptor-2 in Mast Cells in Allergic Airway Inflammation.

Authors:  Sun-Young Kwon; Jae-Hong Kim
Journal:  Int J Mol Sci       Date:  2019-06-14       Impact factor: 5.923

7.  Recombinant ArtinM activates mast cells.

Authors:  Valéria Cintra Barbosa-Lorenzi; Nerry Tatiana Cecilio; Patricia Andressa de Almeida Buranello; Maria Cristina Pranchevicius; Maria Helena S Goldman; Gabriela Pereira-da-Silva; Maria Cristina Roque-Barreira; Maria Célia Jamur; Constance Oliver
Journal:  BMC Immunol       Date:  2016-07-04       Impact factor: 3.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.